CEL-SCI (FRA:LSRM) Accounts Payable & Accrued Expense : €2.60 Mil (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is CEL-SCI Accounts Payable & Accrued Expense?

CEL-SCI's quarterly accounts payable & accrued expense increased from Jun. 2023 (€3.12 Mil) to Sep. 2023 (€3.39 Mil) but then declined from Sep. 2023 (€3.39 Mil) to Dec. 2023 (€2.60 Mil).

CEL-SCI's annual accounts payable & accrued expense increased from Sep. 2021 (€2.38 Mil) to Sep. 2022 (€2.96 Mil) and increased from Sep. 2022 (€2.96 Mil) to Sep. 2023 (€3.39 Mil).

CEL-SCI Accounts Payable & Accrued Expense Historical Data

The historical data trend for CEL-SCI's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CEL-SCI Accounts Payable & Accrued Expense Chart

CEL-SCI Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

2.12

2.53

2.38

2.96

3.39

CEL-SCI Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															2.79	3.23	3.12	3.39	2.60

CEL-SCI Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

CEL-SCI (FRA:LSRM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CEL-SCI Corp (FRA:LSRM) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

CVM:USA

Address

8229 Boone Boulevard, Suite 802, Vienna, VA, USA, 22182

Website

https://www.cel-sci.com

CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The company is focused on activating the immune system to fight cancer and infectious diseases. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.

CEL-SCI (FRA:LSRM) Headlines

No Headlines